What Limits Burst Release in Solvent Evaporation Microspheres Made from B6010-4?

Microsphere encapsulation of small-molecule and peptide APIs with LACTEL 50:50 DL-PLG (B6010-4) is run as an oil-in-water solvent evaporation process. The dispersed phase consists of 8–12 mL dichloromethane containing 800–1,200 mg of the acid-terminated copolymer. The drug-to-polymer ratio is maintained between 1:4 and 1:10 depending on API potency and solubility. The continuous phase is prepared as a 0.5–2.0% w/v poly(vinyl alcohol) solution, 87–89% hydrolyzed, at 15–25 °C. Emulsification is performed on a Silverson L5M-A high-shear mixer at 4,000–7,000 rpm for 3–5 min. The primary emulsion is transferred into a chilled hardening bath held at 2–5 °C using a solvent-to-water ratio of 1:10 v/v. Solvent extraction proceeds for 6–8 h under paddle agitation at 150–300 rpm. Hardened microspheres are wet-sieved to 25–125 µm, rinsed with sterile water, and lyophilized at -40 °C and 0.20 mbar for 24 h.

Residual dichloromethane is controlled below the ICH Q3C concentration limit of 600 ppm for a 10 g daily dose. Particle size distribution is measured by laser diffraction according to ISO 13320:2020; a span above 1.5 correlates with syringe-related defects in terminal suspension products. Endotoxin is controlled at <0.5 EU/mg under USP <85>. The acid-terminated 50:50 ratio increases water uptake relative to ester-capped equivalents, which shortens the diffusion lag phase and raises initial release. Burst release is suppressed by increasing continuous-phase PVA concentration and maintaining the hardening bath below 5 °C because rapid solvent extraction reduces microsphere surface porosity. Terminal products using this microsphere format are typically 30–60 day sustained-release injectable depots. Release is not linear and follows a triphasic profile of initial diffusion, polymer hydration, and erosion-driven drug transport.

Craniofacial screws cannot be considered load-bearing after 6 weeks

Prior to melt processing, LACTEL B6010-4 pellets are vacuum-dried at 55–60 °C under -0.08 MPa for 12–18 h. Karl Fischer titration should show moisture below 250 ppm. A moisture level above 300 ppm causes measurable hydrolysis during extrusion and reduces molecular weight by more than 10% within 5 min at melt temperature. Injection molding of bioresorbable craniofacial screws is carried out on a 20–30 mm screw machine with L/D 20:1 and compression ratio 2.0:1. Barrel zones are set at 95 °C, 105 °C, 115 °C, and 120 °C, with nozzle at 120 °C and mold at 20–25 °C. Clamp force for a multi-cavity tool is typically 100–300 kN. Melt residence time is kept below 5 min because the acid end group accelerates autocatalytic chain scission above the amorphous resin glass transition of 45–50 °C.

Tensile test specimens are molded and conditioned at 23 °C and 50% RH for 48 h before testing per ASTM D638-14 Type V. Typical molded tensile strength for this 50:50 copolymer is in the 40–50 MPa range, with tensile modulus between 2.5 and 3.5 GPa and elongation at break below 5%. These values fall rapidly under physiological conditions. In phosphate-buffered saline at 37 °C and pH 7.4, the acid-terminated 50:50 DL-PLG loses approximately 50% of its molecular weight within 1–2 weeks and undergoes significant mass loss by 6–8 weeks. The resulting fixation device is therefore limited to non-load-bearing or short-term load-sharing craniofacial sites. Sterilization by ethylene oxide is preferred over gamma irradiation. If gamma sterilization is unavoidable, a dose of 25 kGy under ISO 11137 must be validated for molecular weight retention because ionizing radiation induces chain scission in PLGA.

Biocompatibility for this device category is assessed under ISO 10993-5 for cytotoxicity, ISO 10993-10 for sensitization and irritation, and ISO 10993-11 for systemic toxicity. Glycolic acid and lactic acid degradation products are not considered low-molecular-weight leaching hazards, but local pH drop remains an operational concern in poorly vascularized bone.

A confined impinging jet mixer is charged with a 10–20 mg/mL solution of LACTEL B6010-4 in acetone and a 0.1–0.5% w/v aqueous poloxamer 188 stream. Mixing is performed at a solvent-to-antisolvent ratio of 1:9 v/v and a total flow rate of 40–80 mL/min. Rapid solvent displacement yields nanoparticles in the 80–250 nm range with polydispersity index below 0.20 when measured by dynamic light scattering according to ISO 22412:2017 on a Malvern Zetasizer Nano ZS. Zeta potential is typically -20 to -40 mV in 10 mM NaCl at 25 °C; this negative surface charge reduces aggregation during storage. Residual acetone is controlled below the ICH Q3C class 3 limit of 5,000 ppm. Acetone is preferred over dimethylformamide because acetone is a class 3 solvent, whereas DMF carries a class 2 concentration limit of 1,090 ppm for a 10 g daily dose and complicates lyophilized cake reconstitution.

For hydrophobic antineoplastic or anti-inflammatory payloads, drug is pre-dissolved in the acetone phase at a drug-to-polymer ratio of 1:5 to 1:20. Encapsulation efficiency declines when the drug solubility in water exceeds 0.5 mg/mL in the antisolvent stream. The nanoparticle dispersion is concentrated by tangential flow filtration with a 300 kDa membrane and lyophilized with 5–10% w/v trehalose as cryoprotectant. Terminal product is a sterile, lyophilized cake intended for parenteral administration after reconstitution. Syringe filterability is tested by passage through a 0.22 µm polyethersulfone filter at 25 °C using a 10 mL syringe. A filtration flow rate below 2 mL/min triggers a particle size distribution review. The acid-terminated 50:50 copolymer degrades faster than higher-lactide ratios, which limits this nanoparticle platform to release windows of approximately 2–6 weeks.

When N-Methyl-2-pyrrolidone Acts as the Water-Miscible Solvent in an In Situ Forming Depot

LACTEL B6010-4 is dissolved at 30–50 wt% in N-methyl-2-pyrrolidone to form a viscous, injectable solution. The solution is filled into prefilled syringes of 1–5 mL and injected through a 20G–23G needle. Viscosity at 25 °C and 100 s⁻¹ is typically 0.5–5 Pa·s as measured by cone-and-plate rheometry under ISO 3219. Upon contact with aqueous interstitial fluid, NMP diffuses out and water penetrates the polymer solution. Phase inversion forms a solid or semi-solid depot at the injection site. Burst release is governed by the NMP efflux rate and the copolymer concentration. At 30 wt% copolymer, burst release can exceed 20% of the loaded dose in 24 h. At 50 wt%, the burst is generally reduced to 5–15% because the depot solidifies faster and creates a diffusion barrier.

Residual NMP in the finished depot vehicle is evaluated against the ICH Q3C concentration limit of 530 ppm for a 10 g daily dose. Because NMP is not removed after injection but is released gradually, the toxicological justification must include the total NMP dose and body burden. Syringe functionality is evaluated according to ISO 7886-1; break-loose and glide forces are measured with a tensile tester at 100 mm/min and should remain below 40 N to avoid injection failure. Terminal products in this category include subcutaneous or intratumoral depots for oncology, periodontitis, or antipsychotic therapy with a release window of 4–8 weeks. The acid-terminated 50:50 DL-PLG degrades rapidly enough to avoid long-term tissue encapsulation but not so rapidly that the depot disintegrates before the release phase is complete. Process design must also address NMP occupational exposure limits. Closed handling and local exhaust ventilation are required because NMP is classified as a reproductive toxicant under the EU CLP regulation.

Electrospinning of LACTEL B6010-4 uses a ternary solvent system of chloroform and N,N-dimethylformamide at 4:1 v/v, with copolymer concentration between 12 and 18% w/v. The solution is loaded into a 5 mL glass syringe with an 18G blunt stainless-steel needle. Applied voltage is 18–25 kV, flow rate 0.5–1.5 mL/h, and collector distance 12–15 cm. A grounded rotating drum at 500–2,000 rpm is used to produce aligned fibers; random fiber mats are collected on a static plate. Fiber diameter is controlled from 0.5 µm to 3.0 µm by adjusting polymer concentration and DMF fraction. Higher DMF content increases fiber surface porosity but also raises residual solvent load. Residual chloroform must be below the ICH Q3C class 2 limit of 60 ppm, and residual dimethylformamide below 1,090 ppm for a 10 g daily dose.

The resulting nonwoven scaffold is intended for tissue engineering where a 2–6 week provisional matrix is sufficient, such as skin, nerve guidance, or tendon repair. Pore size and fiber alignment are measured by scanning electron microscopy and analyzed according to ASTM F2450. Pores below 10 µm restrict cell infiltration. Tensile properties of the dry mat are measured under ASTM D882-18 using 5 mm wide strips and a gauge length of 10 mm. Dry tensile strength is typically 2–8 MPa with elastic modulus 20–100 MPa; hydration reduces these values by more than 60%. The acid-terminated 50:50 copolymer hydrolyzes faster than poly(D,L-lactide-co-glycolide) with a 75:25 ratio, so mechanical support is lost early. Cytocompatibility is evaluated by extraction under ISO 10993-5; residual solvent removal is critical because DMF and chloroform are cytotoxic at low concentrations.

Ultrasonic Spray Coating Limits for Drug-Eluting Combination Devices

For drug-eluting coatings on implantable combination devices, LACTEL B6010-4 is dissolved in acetone:tetrahydrofuran 3:1 v/v at 1–3 wt% with the API co-dissolved at a drug-to-polymer ratio of 1:3 to 1:10. The solution is delivered to a 48 kHz ultrasonic nozzle at 0.25–1.0 mL/min. Substrate temperature is held at 30–40 °C to accelerate solvent removal without causing surface skinning. Coating thickness is controlled between 3 and 20 µm. Thickness above 25 µm has shown delamination after balloon expansion or stent deployment and is not recommended. Uniformity is inspected by optical profilometry with a target relative standard deviation below 10%. Residual tetrahydrofuran is evaluated against the ICH Q3C concentration limit of 720 ppm for a 10 g daily dose; residual acetone must remain below 5,000 ppm.

Adhesion of the PLGA coating is tested by tape peel according to ASTM D3359-17; a classification of 5B is expected on metallic substrates after plasma cleaning. Drug release from the coated device is profiled in phosphate-buffered saline at 37 °C and pH 7.4 using USP apparatus 7 or a modified USP apparatus 4 for stent-like geometries. The acid-terminated 50:50 DL-PLG releases over 4–8 weeks, which is shorter than 75:25 PLGA formulations and therefore suited to combination products requiring medium-term drug elution without long-term polymer residue. Hemocompatibility testing is performed under ISO 10993-4. Because the copolymer is amorphous and low in glycolide crystallinity, platelet adhesion is generally lower than on more crystalline polymers. Published data for this specific substrate configuration are limited; coating adhesion and release must be revalidated on the actual metallic alloy, surface finish, and device geometry. If the API is moisture-sensitive, the process must be run in a dry nitrogen environment at <10% RH to prevent copolymer hydrolysis before packaging.